The HER2 Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“HER2 Negative Breast Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HER2 Negative Breast Cancer Market.

Some of the key takeaways from the HER2 Negative Breast Cancer Pipeline Report: 

• Companies across the globe are diligently working toward developing novel HER2 Negative Breast Cancer treatment therapies with a considerable amount of success over the years. 
• HER2 Negative Breast Cancer companies working in the treatment market are EnhancedBio Inc, Relay Therapeutics, Inc., Prelude Therapeutics, Ellipses Pharma, Beta Pharma, CytomX Therapeutics, Atossa Therapeutics, Inc, AstraZeneca, Roche, Celcuity, Inc., BeiGene, Olema Pharmaceuticals, Inc., AstraZeneca, Adagene Inc, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Genentech, and others, are developing therapies for the HER2 Negative Breast Cancer treatment 

• Emerging HER2 Negative Breast Cancer therapies in the different phases of clinical trials are- ER-PROTAC, RLY-2608, PRT2527, EP0062, BPI-1178, CX-2009, Z-endoxifen, AZD9833, GDC-9545, Gedatolisib, BGB-290, OP-1250, AZD9833, ADG106, Dato-DXd, HRS8807, Ipatasertib, and others are expected to have a significant impact on the HER2 Negative Breast Cancer market in the coming years.   
• In January 2023, Context Therapeutics Inc., a company dedicated to developing innovative therapies for solid tumors, particularly focusing on female-related cancers, announced that its clinical trial collaborator, Stemline Therapeutics, Inc., a wholly owned subsidiary of The Menarini Group (“Menarini”), has obtained FDA approval for ORSERDU (elacestrant). This approval is specifically for the treatment of postmenopausal women or adult men diagnosed with estrogen receptor–positive (ER+), HER2-negative (HER2-), Estrogen Receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer. This approval is granted for individuals whose disease has progressed despite undergoing at least one line of endocrine therapy.
• On January 27, 2023, The FDA has granted approval for elacestrant (Orserdu) to treat advanced or metastatic breast cancer in postmenopausal women or adult men. Specifically, this approval is for cases where the cancer is estrogen receptor-positive (ER+), HER2-negative, and involves mutations in the Estrogen Receptor 1 gene (ESR1). The approval is for individuals whose cancer has progressed despite undergoing at least one line of endocrine therapy.
• In January 2023, Daiichi Sankyo and AstraZeneca’s ENHERTU® (trastuzumab deruxtecan) obtained approval in the European Union (EU) as a standalone treatment for adult patients diagnosed with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer. This approval is designated for individuals who have previously undergone chemotherapy in the metastatic stage or experienced disease recurrence while undergoing or within six months after completing adjuvant chemotherapy.
• In January 2023, Gilead Sciences, Inc. revealed that the European Medicines Agency (EMA) has validated a Type II variation Marketing Authorization Application (MAA) for Trodelvy (sacituzumab govitecan-hziy) intended for treating adult patients diagnosed with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer. This application is for individuals who have previously undergone endocrine-based therapy and received at least two additional systemic therapies in the metastatic stage.

HER2 Negative Breast Cancer Overview

HER2-negative breast cancer refers to a type of breast cancer where tumor cells do not overexpress a protein called human epidermal growth factor receptor 2 (HER2). HER2 is a protein that plays a role in the growth and division of cells.

Get a Free Sample PDF Report to know more about HER2 Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight

Emerging HER2 Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

• ER-PROTAC: EnhancedBio Inc
• RLY-2608: Relay Therapeutics, Inc.
• PRT2527: Prelude Therapeutics
• EP0062: Ellipses Pharma
• BPI-1178: Beta Pharma
• CX-2009: CytomX Therapeutics
• Z-endoxifen: Atossa Therapeutics, Inc
• AZD9833: AstraZeneca
• GDC-9545: Roche
• Gedatolisib: Celcuity, Inc.
• BGB-290: BeiGene
• OP-1250: Olema Pharmaceuticals, Inc.
• AZD9833: AstraZeneca
• ADG106: Adagene Inc
• Dato-DXd: Daiichi Sankyo, Inc.
• HRS8807: Shanghai Hengrui Pharmaceutical Co., Ltd.
• Ipatasertib: Genentech

HER2 Negative Breast Cancer Route of Administration

HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

HER2 Negative Breast Cancer Molecule Type

HER2 Negative Breast Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

HER2 Negative Breast Cancer Pipeline Therapeutics Assessment

• HER2 Negative Breast Cancer Assessment by Product Type
• HER2 Negative Breast Cancer By Stage and Product Type
• HER2 Negative Breast Cancer Assessment by Route of Administration
• HER2 Negative Breast Cancer By Stage and Route of Administration
• HER2 Negative Breast Cancer Assessment by Molecule Type
• HER2 Negative Breast Cancer by Stage and Molecule Type

DelveInsight’s HER2 Negative Breast Cancer Report covers around 85+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further HER2 Negative Breast Cancer product details are provided in the report. Download the HER2 Negative Breast Cancer pipeline report to learn more about the emerging HER2 Negative Breast Cancer therapies 

Some of the key companies in the HER2 Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for HER2 Negative Breast Cancer are – Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., InventisBio Co., Ltd, Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., and others.

HER2 Negative Breast Cancer Pipeline Analysis:

The HER2 Negative Breast Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Negative Breast Cancer Treatment.
• HER2 Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HER2 Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about HER2 Negative Breast Cancer drugs and therapies

HER2 Negative Breast Cancer Pipeline Market Drivers

• HER2 protein is considered a relevant biomarker for treatment, growing prevalence of Breast Cancer are some of the important factors that are fueling the HER2 Negative Breast Cancer Market.

HER2 Negative Breast Cancer Pipeline Market Barriers

• However, poor understanding in the context of breast cancer subtype, lack of research in identification of factors involved in resistance and other factors are creating obstacles in the HER2 Negative Breast Cancer Market growth.

Scope of HER2 Negative Breast Cancer Pipeline Drug Insight    

• Coverage: Global
• Key HER2 Negative Breast Cancer Companies: EnhancedBio Inc, Relay Therapeutics, Inc., Prelude Therapeutics, Ellipses Pharma, Beta Pharma, CytomX Therapeutics, Atossa Therapeutics, Inc, AstraZeneca, Roche, Celcuity, Inc., BeiGene, Olema Pharmaceuticals, Inc., AstraZeneca, Adagene Inc, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Genentech, and others
• Key HER2 Negative Breast Cancer Therapies: ER-PROTAC, RLY-2608, PRT2527, EP0062, BPI-1178, CX-2009, Z-endoxifen, AZD9833, GDC-9545, Gedatolisib, BGB-290, OP-1250, AZD9833, ADG106, Dato-DXd, HRS8807, Ipatasertib, and others
• HER2 Negative Breast Cancer Therapeutic Assessment: HER2 Negative Breast Cancer current marketed and HER2 Negative Breast Cancer emerging therapies
• HER2 Negative Breast Cancer Market Dynamics: HER2 Negative Breast Cancer market drivers and HER2 Negative Breast Cancer market barriers 

Request for Sample PDF Report for HER2 Negative Breast Cancer Pipeline Assessment and clinical trials

Table of Contents

1. HER2 Negative Breast Cancer Report Introduction

2. HER2 Negative Breast Cancer Executive Summary

3. HER2 Negative Breast Cancer Overview

4. HER2 Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. HER2 Negative Breast Cancer Pipeline Therapeutics

6. HER2 Negative Breast Cancer Late Stage Products (Phase II/III)

7. HER2 Negative Breast Cancer Mid Stage Products (Phase II)

8. HER2 Negative Breast Cancer Early Stage Products (Phase I)

9. HER2 Negative Breast Cancer Preclinical Stage Products

10. HER2 Negative Breast Cancer Therapeutics Assessment

11. HER2 Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. HER2 Negative Breast Cancer Key Companies

14. HER2 Negative Breast Cancer Key Products

15. HER2 Negative Breast Cancer Unmet Needs

16 . HER2 Negative Breast Cancer Market Drivers and Barriers

17. HER2 Negative Breast Cancer Future Perspectives and Conclusion

18. HER2 Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/